|
1
|
Gozuacik D and Kimchi A: DAPk protein
family and cancer. Autophagy. 2:74–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hervouet E, Cheray M, Vallette F and
Cartron P: DNA methylation and apoptosis resistance in cancer
cells. Cells. 2:545–573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen RH, Wang WJ and Kuo JC: The tumor
suppressor DAP-kinase links cell adhesion and cytoskeleton
reorganization to cell death regulation. J Biomed Sci. 13:193–199.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang X, Wu W, Sun SY, et al:
Hypermethylation of the death-associated protein kinase promoter
attenuates the sensitivity to TRAIL-induced apoptosis in human
non-small cell lung cancer cells. Mol Cancer Res. 2:685–691.
2004.
|
|
5
|
Raveh T and Kimchi A: DAP kinase - a
proapoptotic gene that functions as a tumor suppressor. Exp Cell
Res. 264:185–192. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen C, Wang W, Kuo J, et al:
Bidirectional signals tranduced by DAPK-ERK interaction promote the
apoptotic effect of DAPK. EMBO J. 24:294–304. 2005. View Article : Google Scholar :
|
|
7
|
Grønbæk K, Hother C and Jones P:
Epigenetic changes in cancer. APMIS. 115:1039–1059. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raynal NJ, Si J, Taby RF, et al: DNA
methylation does not stably lock gene expression but instead serves
as a molecular mark for gene silencing memory. Cancer Res.
72:1170–1181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tarfiei G, Noruzinia M, Soleimani M, et
al: ROR2 promoter methylation change in osteoblastic
differentiation of mesenchymal stem cells. Cell J. 13:11–15.
2011.PubMed/NCBI
|
|
10
|
Nazor KL, Altun G, Lynch C, et al:
Recurrent variations in DNA methylation in human pluripotent stem
cells and their differentiated derivatives. Cell Stem Cell.
10:620–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bocker MT, Hellwig I, Breiling A, et al:
Genome-wide promoter DNA methylation dynamics of human
hematopoietic progenitor cells during differentiation and aging.
Blood. 117:e182–e189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pattani K, Soudry E, Glazer C, et al:
MAGEB2 is activated by promoter demethylation in head and neck
squamous cell carcinoma. PLoS One. 7:e455342012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stefanska B, Huang J, Bhattacharyya B, et
al: Definition of the landscape of promoter DNA hypomethylation in
liver cancer. Cancer Res. 71:5891–5903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song IS, Ha GH, Kim JM, et al: Human
ZNF312b oncogene is regulated by Sp1 binding to its promoter region
through DNA demethylation and histone acetylation in gastric
cancer. Int J Cancer. 129:2124–2133. 2011. View Article : Google Scholar
|
|
15
|
Lavelle D, DeSimone J, Hankewych M,
Kousnetzova T and Chen YH: Decitabine induces cell cycle arrest at
the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP
kinase pathway. Leuk Res. 27:999–1007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohana Kumar B, Jin HF, Kim JG, et al: DNA
methylation levels in porcine fetal fibroblasts induced by an
inhibitor of methylation, 5-azacytidine. Cell Tissue Res.
325:445–454. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al-Romaih K, Sadikovic B, Yoshimoto M, et
al: Decitabine-induced demethylation of 5′ CpG island in GADD45A
leads to apoptosis in osteosarcoma cells. Neoplasia. 10:471–480.
2008.PubMed/NCBI
|
|
18
|
Issa J, Gharibyan V, Cories J, et al:
Phase II study of low-dose decitabine in patients with chronic
myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol.
23:3948–3956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oki Y, Kantarjian H, Gharibyan V, et al:
Phase II study of low-dose decitabine in combination with imatinib
mesylate in patients with accelerated or myeloid blastic phase of
chronic myelogenous leukemia. Cancer. 109:899–906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahmad S, Arjumand W, Seth A, Saini A and
Sultana S: Methylation of the APAF-1 and DAPK-1 promoter region
correlates with progression of renal cell carcinoma in North Indian
population. Tumor Biol. 33:395–402. 2012. View Article : Google Scholar
|
|
21
|
Banzai C, Nishnio K, Quan J, et al:
Gynecological Cancer Registry of Niigata: Promoter methylation of
DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma. Int J
Clin Oncol. 19:127–132. 2014. View Article : Google Scholar
|
|
22
|
Kristensen LS, Treppendahl MB, Asmar F, et
al: Investigation of MGMT and DAPK1 methylation patterns in diffuse
large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep.
3:27892013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Claus R, Hackanson B, Poetsch AR, et al:
Quantitative analyses of DAPK1 methylation in AML and MDS. Int J
Cancer. 131:E138–E142. 2012. View Article : Google Scholar :
|
|
24
|
Katzenellenbogen R, Baylin S and Herman J:
Hypermethylation of the DAP-kinase CpG island is a common
alteration in B-cell malignancies. Blood. 93:4347–4353.
1999.PubMed/NCBI
|
|
25
|
Mir R, Ahmad I, Javid J, et al: Epigenetic
silencing of DAPK1 gene is associated with faster disease
progression in India populations with chronic myeloid leukemia. J
Cancer Sci Ther. 5:144–149. 2013. View Article : Google Scholar
|
|
26
|
Qian J, Wang YL, Lin J, et al: Aberrant
methylation of the death-associated protein kinase 1 (DAPK1) CpG
island in chronic myeloid leukemia. Eur J Haematol. 82:119–123.
2009. View Article : Google Scholar
|
|
27
|
Yanagisawa K, Yamauchi H, Kaneko M, et al:
Suppression of cell proliferation and the expression of a bcr-abl
fusion gene and apoptotic cell death in a new human chronic
myelogenous leukaemia cell line, KT-1, by interferon-α. Blood.
91:641–648. 1998.PubMed/NCBI
|
|
28
|
Vigneri P and Wang JY: Induction of
apoptosis in chronic myelogenous leukaemia cells through nuclear
entrapment of BCR-ABL tyrosine kinase. Nat Med. 7:228–234. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Litzow MR: Imatinib resistance: obstacles
and opportunities. Arch Pathol Lab Med. 130:669–679.
2006.PubMed/NCBI
|
|
30
|
Walz C and Sattler M: Novel targeted
therapies to overcome imatinib mesylate resistance in chronic
myeloid leukaemia (CML). Crit Rev Oncol Hematol. 57:145–164. 2006.
View Article : Google Scholar
|
|
31
|
Corbin AS, Rosée P, Stoffregen EP, Druker
BJ and Deininger MW: Several Bcr-Abl kinase domain mutants
associated with imatinib mesylate resistance remain sensitive to
imatinib. Blood. 101:4611–4614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roche-Lestienne C, Soenen-Cornu V,
Grardel-Duflos N, et al: Several types of mutations of the Abl gene
can be found in chronic myeloid leukemia patients resistant to
STI571, and they can pre-exist to the onset of treatment. Blood.
100:1014–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kang HY, Hwang JY, Kim SH, et al:
Comparison of allele specific oligonucleotide-polymerase chain
reaction and direct sequencing for high throughput screening of ABL
kinase domain mutations in chronic myeloid leukemia resistant to
imatinib. Haematologica. 91:659–662. 2006.PubMed/NCBI
|
|
34
|
Tang X, Khuri FR, Lee JJ, et al:
Hypermethylation of the death-associated protein (DAP) kinase
promoter and aggressiveness in stage non-small-cell lung cancer. J
Natl Cancer Inst. 92:1511–1516. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawaguchi K, Oda Y, Saito T, et al:
Death-associated protein kinase (DAP kinase) alteration in soft
tissue leiomyosarcoma: Promoter methylation or homozygous deletion
is associated with a loss of DAP kinase expression. Hum Pathol.
35:1266–1271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wong TS, Chang HW, Tang KC, et al: High
frequency of promoter hypermethylation of the death-associated
protein-kinase gene in nasopharyngeal carcinoma and its detection
in the peripheral blood of patients. Clin Cancer Res. 8:433–437.
2002.PubMed/NCBI
|
|
37
|
Voso MT, Gumiero D, D’alo’ F, et al:
DAP-kinase hypermethylation in the bone marrow of patients with
follicular lymphoma. Haematologica. 91:1252–1256. 2006.PubMed/NCBI
|
|
38
|
Uehara E, Takeuchi S, Yang Y, et al:
Aberrant methylation in promoter-associated CpG islands of multiple
genes in chronic myelogenous leukemia blast crisis. Oncol Lett.
3:190–192. 2012.PubMed/NCBI
|
|
39
|
Satoh A, Toyota M, Itoh F, et al: DNA
methylation and histone deacetylation associated with silencing DAP
kinase gene expression in colorectal and gastric cancers. Br J
Cancer. 86:1817–1823. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He YF, Li BZ, Li Z, et al: Tet-Mediated
ormation of 5-carboxylcytosine and its excision by TDG in mammalian
DNA. Science. 333:1303–1307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ito S, Shen L, Dai Q, et al: Tet proteins
can convert 5-methylcytosine to 5-formylcytosine and
5-carboxylcytosine. Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tahiliani M, Koh KP, Shen YH, et al:
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang Y, Pastor WA, Shen Y, et al: The
behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS
One. 5:e88882010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nestor C, Ruzov A, Meehan R and Dunican D:
Enzymatic approaches and bisulfite sequencing cannot distinguish
between 5-methylcytosine and 5-hydroxymethylcytosine in DNA.
Biotechniques. 48:317–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yu M, Hon GC, Szulwach KE, et al:
Base-resolution analysis of 5-hydroxymethylcytosine in the
mammalian genome. Cell. 149:1368–1380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu M, Hon GC, Szulwach KE, et al:
Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. Nat
Protoc. 7:2159–2170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang Y, Pastor WA, Zepeda-Martínez JA and
Rao A: The anti-CMS technique for genome-wide mapping of
5-hydroxymethylcytosine. Nat Protoc. 7:1897–1908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu X, Song CX, Szulwach K, et al: Chemical
modification-assisted bisulfite sequencing (CAB-Seq) for
5-carboxylcytosine detection in DNA. J Am Chem Soc. 135:9315–9317.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cilloni D and Saglio G: Molecular
pathways: BCR-ABL. Clin Cancer Res. 18:930–937. 2012. View Article : Google Scholar
|
|
50
|
Anjum R, Roux PP, Ballif BA, Gygi SP and
Blenis J: The tumor suppressor DAP kinase is a target of
RSK-mediated survival signaling. Curr Biol. 15:1762–1767. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Quentmeier H, Eberth S, Romani J, Zaborski
M and Drexler HG: BCR-ABL1-independent PI3Kinase activation causing
imatinib-resistance. J Hematol Oncol. 4:62011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
La Rosée P, Johnson K, Corbin AS, et al:
In vitro efficacy of combined treatment depends on the underlying
mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell
lines. Blood. 103:208–215. 2004. View Article : Google Scholar
|
|
53
|
Howell PM Jr, Liu Z and Khong HT:
Demethylating agents in the treatment of cancer. Pharmaceuticals.
3:2022–2044. 2010. View Article : Google Scholar
|
|
54
|
Hochhaus A, Kreil S, Corbin AS, et al:
Molecular and chromosomal mechanisms of resistance to imatinib
(STI571) therapy. Leukemia. 16:2190–2196. 2002. View Article : Google Scholar : PubMed/NCBI
|
